Sign in
TerminatedPhase 3

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

Key facts

Who runs it
Eyenovia Inc.
Where
Azusa, Berkeley, Birmingham, Brentwood, Chicago, Columbus, Cranberry Township, Downers Grove, Glendale, High Point, Los Angeles, Memphis, Nashville, New York, Philadelphia, Raleigh, San Diego, and Virginia Beach, United StatesSee the 18 sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
438 people enrolled
Started
3 Jun 2019
Ended
20 Nov 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Atropine 0.1% Ophthalmic Solution
  • Atropine 0.01% Ophthalmic Solution
  • Placebo Ophthalmic Solution
Record updated
6 January 2025
Why it stopped
Interim Analysis reviewed by Data Monitoring Committee indicated futility

Who can take part

Age
3 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Refractive error by cycloplegic autorefraction: myopia -1.00 D to -6.00 D in both eyes; astigmatism ≤ 1.50 D in both eyes; anisometropia < 1.50 D
  • Best-corrected distance visual acuity in current correction of 0.2 logMAR or better with interocular difference ≤ 0.1 logMAR
  • Refractive correction for each eye meets the following criteria: myopia within ± 0.50 D of the manifest refraction at the Screening Visit; cylinder power within ± 0.50 D of the manifest refraction at the Screening Visit; when cylinder power is < 1.00 D, axis within ± 15 degrees of the manifest refraction; when cylinder power is ≥ 1.00 D, axis within ± 5 degrees of the manifest refraction

Who cannot take part

  • Current or previous myopia treatment with non-study atropine, pirenzepine or other topical anti-muscarinic agent
  • Current or prior history of manifest strabismus, amblyopia, or nystagmus
  • Prior eyelid, strabismus, intraocular, or refractive surgery
  • Participation in any study of an investigational, interventional product within 30 days prior to Screening Visit
  • Known atropine allergy
  • History of premature birth by parent's report
  • Inability to perform protocol-prescribed testing due to preexisting neurological diagnoses, genetic syndrome, or other issues
  • Medical conditions predisposing patient to degenerative myopia, abnormal ocular refractive anatomy, and/or any history of intraocular surgery
  • Any systemic disease or condition that may affect visual function or development such as diabetes mellitus
  • History of punctal occlusion
  • Presence of a severe/serious ocular condition or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment or follow-up
  • Current use of bifocals, progressive-addition lenses, or multifocal soft contact lenses
  • Use of rigid gas permeable lenses, including orthokeratology lenses within 90 days of Screening
  • Abnormality of the cornea, lens, central retina, iris or ciliary body
  • Intraocular pressure > 26 mmHg
  • Any ocular inflammation or external ocular inflammation within 30 days of Screening
  • Heterochromia
  • Lid squeezers
  • Immediate family member of study staff designed to perform study evaluations or procedures
  • Pregnancy, or if sexually active, unwillingness to use an acceptable form of contraception during the study

Where in United States

  • Canyon City EyecareAzusa, United States
  • UC BerkeleyBerkeley, United States
  • University of Alabama at Birmingham School of OptometryBirmingham, United States
  • Primary Eyecare GroupBrentwood, United States
  • Illinois College of OptometryChicago, United States
  • The Ohio State University College of OptometryColumbus, United States
  • Scott & Christie and AssociatesCranberry Township, United States
  • Midwestern UniversityDowners Grove, United States
  • Midwestern UniversityGlendale, United States
  • Wake Forest Health Network Ophthalmology - Oak HollowHigh Point, United States
  • Marshall Ketchum University College of OptometryLos Angeles, United States
  • Southern College of OptometryMemphis, United States
  • Vanderbilt University Medical CenterNashville, United States
  • SUNY College of OptometryNew York, United States
  • Salus University - The Eye InstitutePhiladelphia, United States
  • Oculus ResearchRaleigh, United States
  • Ratner Children's Eye CenterSan Diego, United States
  • Virginia Pediatric Eye CenterVirginia Beach, United States

About the trial

What the trial wants to find out

This study evaluates the progression of myopia in participants using microdosed atropine 0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer study medication daily in each eye for 48 months. Efficacy and safety assessments will be performed at visits scheduled for 1, 6, 12, 18, 24, 30 and 36 months after initiation of medication use. Subjects will be re-randomized at the 36 month visit, then followed at 6 month intervals for an additional year.

The 3 groups in the trial

  • Atropine 0.1% Ophthalmic SolutionTreatment being tested

    Atropine 0.1% ophthalmic solution administered daily in both eyes using a microdose dispenser

  • Atropine 0.01% Ophthalmic SolutionTreatment being tested

    Atropine 0.01% ophthalmic solution administered daily in both eyes using a microdose dispenser

  • Placebo Ophthalmic SolutionPlacebo, for comparison

    Placebo ophthalmic solution administered daily in both eyes using a microdose dispenser

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)
Record updated
6 January 2025